Desonide
Active ingredient · 2 therapeutic classes
- Drug class
- Corticosteroids, Moderately Potent (Group Ii)
- Availability
- Prescription only
- Routes
- Topical
- Markets covered
- 2
- Products on record
- 7
- FDA reports (12 mo)
- 335
Overview
Desonide is an active pharmaceutical ingredient in the Corticosteroids, Moderately Potent (Group Ii) group (D07AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 4 | March 22, 2025 |
| US United States | FDA | 3 | April 1, 2026 |
CACanada· Health Canada
4 products
How to take
05% Cream or Ointment should be applied to the affected skin thoroughly covering the area. The usual dosage is two to three times daily; however, this may be increased in the treatment of refractory cases. pdp-DESONIDE Cream contains the following non-medicinal ingredients: aluminum sulfate, calcium acetate, dextrin, glycerin, kolliphor, light mineral oil, methylparaben, purified water, sodium lauryl sulfate, wax, white petrolatum.
pdp-DESONIDE Ointment contains the following non-medicinal ingredient: white petrolatum.
AVAILABILITY OF DOSAGE FORMS pdp-DESONIDE Cream:
Supplied in tubes of 15 grams and 60 grams. pdp-DESONIDE Ointment: Supplied in tubes of 60 grams. Store below 30°C. Avoid freezing. PHARMACOLOGY Since the introduction of hydrocortisone for the topical treatment of various dermatological disorders, a great many analogs have been synthesized in attempts to increase potency and reduce side effects.
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
How to take
Drug interactions
Known interactions involving Desonide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02229315 · revised March 22, 2025
- [2]FDA DailyMed · 0665dd04-1d0b-45… · revised July 19, 2023 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.